
|Videos|December 18, 2019
Frontline TKI in Intermediate-Risk Renal Cell Carcinoma
Frontline TKI in Intermediate-Risk Renal Cell Carcinoma
Advertisement
Case: A 70-Year-Old Man with Intermediate-Risk RCC
A 70-year-old Caucasian man presented to ER complaining of blood in his urine and abdominal pain.
H & P
- History of ulcerative colitis, controlled hypertension, and controlled hypercholesterolemia
- Lower back tender to touch
Labs
- CBC: Hgb 12.5 g/dL, HCT, PLT, WBC all WNL
- BP: WNL
- Lipid panel: WNL
Imaging
- Bone CT scan of the chest, abdomen, and pelvis showed a bilateral renal mass, a small lytic lesion in the lumbar vertebrae, several pulmonary nodules, and mediastinal and right hilar lymphadenopathy.
- Diagnosis: stage IV clear-cell renal cell carcinoma; intermediate-risk
Treatment
- Received cytoreductive nephrectomy
- He was started on cabozantinib 60 mg daily
Follow-up
- At 3 weeks of therapy patient tolerated treatment well, with mild fatigue and diarrhea, HTN remains controlled; blood in urine and lower back pain resolved; ECOG 0
- At 6 weeks of therapy the patient shows PR and reduction in size of the renal masses and lymphadenopathy.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Panel Votes 10-3 In Favor of RP1 Plus Nivolumab for Advanced Melanoma
2
Improving Survival, Quality of Life, and Cost-Effectiveness for Allo-HCT
3
FDA Grants Priority Review to Subcutaneous Amivantamab for Advanced HNSCC
4
NCCN Lists Gedatolisib Regimens as Preferred Option in HR+/HER2– Metastatic Breast Cancer
5



































